Aurinia Pharmaceuticals Inc. (AUPH) stock
Close on Nov 11, 2026Market cap $2.17BP/E 7.1Yield –
Aurinia Pharmaceuticals Inc. grew revenue 21.0% to $321.74M over the twelve months to Sep 30, 2026. Operating income rose 123.4% to $156.37M, moving the operating margin from 26.3% to 48.6%. At the latest close the market valued the company at $2.17B, 7.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.17B
- P/E ratio
- 7.1
- Price to sales
- 6.75
- Price to book
- 3.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $321.74M
- Net income
- $314.27M
- EPS, diluted
- $2.29
- Book value per share
- $4.86
- Diluted shares
- 135M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $16.30
- Open
- $16.28
- Day's range
- $15.75 – $16.36
- Volume
- 1,591,179
- Average volume (20 days)
- 926,292
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000 (since Aug 2022)
- Beta (5 years)
- 1.07
- 52-week range
- $13.52 – $19.25
- RSI (14 days)
- 45.3
- Volatility (1 year)
- 35.8%
- Relative volume
- 1.60×
- WACC
- 10.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AUPH | S&P 500 | Difference | AUPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.6% | -2.4% | −0.2 pts | ||
| 3 months | +5.5% | -1.2% | +6.6 pts | ||
| Year to date | +1.6% | +12.3% | −10.7 pts | ||
| 1 year | +3.4% | +12.4% | −9.1 pts | ||
| 3 years | +109.4% | +78.8% | +30.6 pts | +27.9% | +21.4% |
| 5 years | -43.9% | +75.2% | −119.1 pts | -10.9% | +11.9% |
| 10 years | +417.9% | +311.1% | +106.8 pts | +17.9% | +15.2% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aurinia Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Update
- Results
About Aurinia Pharmaceuticals
Pharmaceutical Preparations
Aurinia is a biopharmaceutical company that develops and commercializes medical therapies for individuals affected by autoimmune conditions. The company's principal commercial product is voclosporin, branded as Lupkynis, an oral calcineurin inhibitor prescribed for adult patients suffering from active lupus nephritis. Additionally, the company is developing aritinercept, an investigational dual inhibitor targeting cytokines that regulate B-cell activity for autoimmune disorders. In the United States, Aurinia supplies Lupkynis directly to a specialty distributor alongside two specialty pharmacies. For international markets, it provides commercial inventory to its collaboration partner, Otsuka Pharmaceutical, which handles distribution across Europe and Japan.
Company profile, executives and historyAurinia Pharmaceuticals stock: common questions
What is Aurinia Pharmaceuticals's stock price?
AUPH closed at $16.21 on Nov 11, 2026, down 0.55% on the day. Over the past 52 weeks it traded between $13.52 and $19.25.
What is Aurinia Pharmaceuticals's market cap?
Aurinia Pharmaceuticals was worth $2.17B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AUPH's P/E ratio?
AUPH trades at 7.1 times earnings, based on diluted earnings per share of $2.29 over the twelve months to Sep 30, 2026.
How much revenue does Aurinia Pharmaceuticals make?
Aurinia Pharmaceuticals reported revenue of $321.74M for the twelve months to Sep 30, 2026, up 21.0% from a year earlier.
Does Aurinia Pharmaceuticals pay a dividend?
No. Aurinia Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Aurinia Pharmaceuticals report earnings next?
Aurinia Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AUPH stock performed over the past year?
Including dividends, AUPH returned +3.4% over the past year, against +12.4% for the S&P 500.
How many AUPH shares are sold short?
7M shares were sold short at the latest FINRA report, 6.44% of the float, or 10.3 days of average trading volume.
Who are Aurinia Pharmaceuticals's competitors?
Companies most similar to Aurinia Pharmaceuticals by business, industry and size include AKBA, KNSA, ARQT, XERS, ARDX.
See a number that looks wrong?